To date, no studies have been published assessing serum RLN2 levels in patients with colorectal cancer, making our work the first clinical serum-based evaluation of RLN2 in CRC and a unique contribution to the development of knowledge about biomarkers for this disease. Here, RLN2 is linked to colorectal cancer.